Navigation Links
Actavis' NDA for Progestin-Only Patch Accepted for Filing by FDA
Date:5/13/2013

PARSIPPANY, N.J., May 13, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' New Drug Application (NDA) for a progestin-only transdermal contraceptive patch (Norethindrone Transdermal Delivery System) for use by women to prevent pregnancy. 

The acceptance of the NDA for filing means FDA has determined that the application is sufficiently complete to permit a substantive review.  The acceptance for filing does not provide any assurance that the FDA will ultimately approve the NDA.  Under the Prescription Drug User Fee Act (PDUFA), the FDA's goal under standard review is to review and act on the NDA by December 27, 2013.Actavis' progestin-only patch is designed to provide continuous delivery of norethindrone to the systemic circulation during a once-weekly, seven-day dosing regimen.  Once-weekly dosing with the patch may improve compliance and convenience in progestin-only contraceptive users, as well as provide more consistent average plasma norethindrone levels than oral progestin-only products.

The NDA includes data from a 12-month, multicenter, open-label clinical trial conducted in the U.S., in accordance with FDA guidance for a contraceptive study.  Actavis submitted the NDA to the FDA on February 26, 2013.

About ActavisActavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.  The Company has global and U.S. headquarters in Parsippany, New Jersey, USA. 

Operating as Actavis Pharma, the Company develops, manufactures and markets generic, branded generic, legacy brands and
'/>"/>

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Actavis Cancels Presentation at Bank of America Merrill Lynch Healthcare Conference
2. Actavis Confirms Early Stage Discussions Regarding Potential Combination with Warner Chilcott plc
3. Actavis, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
4. Actavis First Quarter 2013 Net Revenue Increases 24% to $1.9 Billion
5. Actavis Acquires Worldwide Rights for Valeants Metronidazole 1.3% Vaginal Gel
6. Actavis, Inc. to Host First Quarter 2013 Earnings Conference Call and Webcast
7. Former Clinton Deputy Solicitor General sheds light on flaws in Federal Trade Commissions case in FTC v. Actavis Inc.
8. Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference
9. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
10. Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
11. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
(Date:1/15/2014)... 15, 2014  In an unprecedented effort to curb the spread of ... other transport vehicles, an advanced and portable UV germicidal lamp manufactured ... first time. In order to prevent EMS paramedics ... West Palm Beach Fire Rescue is the ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... for Tuesday, December 9 at 11:00 am ET to Discuss ... , SOUTH SAN FRANCISCO, Calif., Dec. ... SNSS ), a biopharmaceutical company focused on the development and ... its studies of voreloxin in acute myeloid leukemia (AML) will ...
... 1 Vical Incorporated (Nasdaq: VICL ) announced ... Merck & Co., Inc. based on Merck,s planned initiation of ... (pDNA) cancer vaccine. The candidate vaccine is based on Vical,s ... (hTERT). hTERT is the subject of separate license agreement. , ...
Cached Medicine Technology:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2
(Date:7/9/2014)... type of lung cancer, researchers have uncovered mutations in ... tumors. The new knowledge may expand treatments for patients ... are available or are in clinical trials. , Reporting ... Cancer Genome Atlas (TCGA), including researchers at Washington University ... and other institutions, studied tumors from 230 patients with ...
(Date:7/9/2014)... injection drug users in Russia might contribute to ... study, conducted by researchers from Boston University Schools ... St. Petersburg Pavlov State University, sought to discover ... outcomes of a cohort of HIV-positive people with ... were arrested by police were more likely to ...
(Date:7/9/2014)... been a sharp increase in the number of cancer ... online, interactive service that allows patients to view laboratory ... appointments, and renew prescriptions. , Over a six-year period, ... each year increased five-fold, while the number of total ... a study by Dr. David Gerber , Associate ...
(Date:7/9/2014)... smell of flatulence and have a reputation for being highly ... sulfide is now being being found to offer potential health ... heart attacks and dementia. A new compound (AP39), designed and ... to future therapies, by targeting delivery of very small amounts ... cells. , Scientists in Exeter have already found that ...
(Date:7/9/2014)... Small print and poor printing on prescription labels ... may lead to errors in taking medication, according ... and CNIB (Canadian National Institute for the Blind)., ... Pharmacists Journal , found that labels on prescription ... professionally recommended guidelines for legibility. , By simply ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... only soybean oil to provide the highest level of ... clean taste., IOWA CITY, Iowa, Feb. 12 An ... only meets the increasing,consumer demand for low trans fat foods, ... so important to food processors., Asoyia Mid Oleic Ultra ...
... N.J., Feb. 12 TeamStaff, Inc.,(Nasdaq: ... and administrative,staffing services, announced today that it ... division, RS Staffing Services, Inc., to TeamStaff,Government ... Georgia based subsidiary currently provides medical, office,administration ...
... Should be considered along with LDL cholesterol ... 12 (HealthDay News) -- A new study showing ... of cardiac trouble strengthens the case for including ... , "Triglycerides traditionally have been viewed as second-class ...
... the recent announcement by,the United States Food and Drug ... Cosmetic (botulinum toxin type A), customers are,looking for alternatives ... FDA approval in 2002 for the temporary treatment of,moderate ... 18 to 65 years,of age. In its recent communication, ...
... DALLAS, Feb. 12 The Beryl Companies announced ... president of product management,and marketing. In this newly ... at a time when new services are being ... strategies., "Mark is a welcome addition to ...
... Association Join Forces to,Educate, African-Americans on Managing ... Feb. 12 A recent survey,commissioned by the ... among African-Americans, two out of three (61,percent) expressed ... of,five (40 percent) expressed concern about developing Alzheimer,s. ...
Cached Medicine News:Health News:Asoyia Announces New Mid Oleic Ultra Low Lin Soybean Oil 2Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 2Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 3Health News:Triglycerides Linked to Coronary Disease Risk 2Health News:Triglycerides Linked to Coronary Disease Risk 3Health News:Botox Cosmetic Alternatives Are Available: Surgical Procedures Offer Solution for Wrinkles 2Health News:New Survey Shows African-Americans Are Concerned With Heart Health but Unaware of Link to Brain Health 2Health News:New Survey Shows African-Americans Are Concerned With Heart Health but Unaware of Link to Brain Health 3Health News:New Survey Shows African-Americans Are Concerned With Heart Health but Unaware of Link to Brain Health 4
... The Sidekick Testing System is the smallest ... System is there when you need it ... or suitcase, or simply in your purse or ... take wherever you go. And, because it's so ...
Inquire...
Inquire...
... Tube is a cost-effective method of providing ... your patient. The warming tube is ideal ... Cath. Lab., and Radiology. The CSZ Warming ... warm patients since it may be used ...
Medicine Products: